Intellia Therapeutics Inc

NTLA

Add to Watchlist

13.670USD

+0.580+4.43%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Intellia Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

120 / 382

Overall Ranking

246 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Intellia Therapeutics Inc Highlights

StrengthsRisks

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 86.55% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 67.67M.

Fairly Valued

The company’s latest PE is -3.89, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 115.59M shares, decreasing 10.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.61K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.97.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

26.737

Target Price

+104.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Intellia Therapeutics Inc is 6.34, ranking 254 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 15.05M, representing a year-over-year decrease of 9.50%, while its net profit experienced a year-over-year decrease of 15.83%.

Score

Industry at a Glance

Previous score

6.34

Change

0



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.74

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Intellia Therapeutics Inc is 5.96, ranking 336 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.89, which is -69.12% below the recent high of -1.20 and -120.41% above the recent low of -8.57.

Score

Industry at a Glance

Previous score

5.96

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Intellia Therapeutics Inc is 7.13, ranking 310 out of 382 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 106.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.13

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Intellia Therapeutics Inc is 7.03, ranking 109 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.51 and the support level at 11.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.81

Change

0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Intellia Therapeutics Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 86.89%, representing a quarter-over-quarter decrease of 4.63%. The largest institutional shareholder is Catherine Wood, holding a total of 14.51M shares, representing 10.38% of shares outstanding, with 17.33% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

14.21M

+19.20%

BlackRock Institutional Trust Company, N.A.

8.35M

+9.86%

State Street Investment Management (US)

6.42M

+29.13%

D. E. Shaw & Co., L.P.

5.33M

+139.23%

Two Sigma Investments, LP

5.05M

+9.37%

Regeneron Pharmaceuticals Inc

3.70M

--

Geode Capital Management, L.L.C.

2.70M

+4.15%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Intellia Therapeutics Inc is 2.36, ranking 221 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.92. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Intellia Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Intellia Therapeutics Inc

NTLA

6.25 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment